Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, skin and soft‑tissue infections, and is used in Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres, oncology centres and clinics worldwide.

Klacid (clarithromycin) is indicated for bacterial infections affecting the respiratory tract, sinuses, skin and soft tissues, and for use in Helicobacter pylori eradication regimens.

- Community‑acquired pneumonia: achieves bacterial clearance and clinical improvement. - Acute bacterial sinusitis: resolves sinus infection symptoms and eradicates causative pathogens. - Acute bacterial exacerbations of chronic bronchitis: reduces bacterial load and improves airflow symptoms. - Skin and soft‑tissue infections: treats cellulitis, erysipelas and other bacterial skin infections. - Helicobacter pylori eradication regimens: contributes to eradication when combined with other agents.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Altered taste (metallic)

Serious or Rare Side Effects: - Hepatotoxicity - QT interval prolongation - Severe allergic reactions (anaphylaxis)

Clarithromycin should be used with caution in specific clinical situations. - Liver function assessment: evaluate hepatic status before initiating therapy. - Cardiac monitoring: avoid in patients with known QT prolongation or when combined with other QT‑prolonging agents. - Renal impairment: adjust therapy and monitor renal function. - Hypersensitivity: discontinue if allergic reactions occur. - Dose adjustment: consider in patients with severe hepatic dysfunction. - Store at room temperature: keep in the original container, protect from moisture and light.

Clarithromycin may interact with several medications.

Major Interactions (Avoid): - QT‑prolonging drugs (e.g., certain antiarrhythmics) – increased risk of cardiac arrhythmias. - CYP3A4 substrates (e.g., some statins, ergot alkaloids) – elevated plasma concentrations. - Warfarin – may enhance anticoagulant effect and increase INR.

Moderate Interactions (Monitor Closely): - Digoxin – potential increase in serum digoxin levels. - Carbamazepine – may reduce clarithromycin concentrations. - Oral contraceptives – possible reduction in contraceptive efficacy.